Company Encyclopedia
View More
name
Oncology Institute
TOI.US
The Oncology Institute, Inc., an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, counseling services, and 24/7 patient assistance services. The company also provides and manages clinical trials, palliative care programs, stem cell transplants services, other care delivery models associated with non-community-based academic, and tertiary care settings; and conducts clinical trials for a range of pharmaceutical, and medical device companies.
179.73 B
TOI.USMarket value -Rank by Market Cap -/-

Financial Score

14/11/2025 Update
C
Health Care FacilitiesIndustry
Industry Ranking16/22
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-535.32%E
    • Profit Margin-15.53%D
    • Gross Margin14.61%D
  • Growth ScoreC
    • Revenue YoY17.53%B
    • Net Profit YoY7.49%C
    • Total Assets YoY-11.03%E
    • Net Assets YoY-130.76%E
  • Cash ScoreC
    • Cash Flow Margin-784.08%E
    • OCF YoY17.53%B
  • Operating ScoreA
    • Turnover2.5A
  • Debt ScoreE
    • Gearing Ratio105.62%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Noble Financial Remains a Buy on Oncology Institute (TOI)

    Noble Financial analyst Robert LeBoyer reiterated a Buy rating on Oncology Institute with a price target of $8.00. Despite LeBoyer's average return of -9.2% and a 28.57% success rate, Oncology Institute also received a Buy rating from BTIG's David Larsen. However, TR | OpenAI – 4o maintained a Hold rating on the stock.

    Tip Ranks·
    US
    TOI
    +32.47%
    Tip Ranks·
    US
    TOI
    +32.47%

    Oncology Institute Projects Strong 2025 Revenue Growth

    Oncology Institute Projects Strong 2025 Revenue Growth

    Tip Ranks·
    US
    TOI
    +32.47%
    Tip Ranks·
    US
    TOI
    +32.47%

    Oncology Institute | 10-Q: FY2025 Q3 Revenue: USD 136.56 M

    LB filings·
    US
    TOI
    +32.47%
    LB filings·
    US
    TOI
    +32.47%

    Oncology Institute Q3 revenue jumps, partly on organic growth in Florida, Oregon

    Oncology Institute's Q3 revenue increased by 36.7% year-over-year, driven by organic growth in Florida and Oregon. The net loss widened slightly to $16.5 million. The company updated its full-year revenue guidance to $495-$505 million and revised its Adjusted EBITDA guidance. Fee-for-service revenue grew 13%, and pharmacy records contributed significantly. Analysts rate the shares as "buy," with a median price target of $7.00, 51% above the current price.

    Reuters·
    US
    TOI
    +32.47%
    Reuters·
    US
    TOI
    +32.47%

    Oncology Institute | 8-K: FY2025 Q3 Revenue: USD 136.56 M

    LB filings·
    US
    TOI
    +32.47%
    LB filings·
    US
    TOI
    +32.47%